The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
No human trial data for the combination. Animal data exists for each component individually; the combination specifically has not been studied in a controlled setting.
The healing evidence is compelling in animal models and consistent across thousands of community reports, but the human translation is completely untested. Nobody knows the right dose, the right cycle, or the right route for humans. The community has converged on protocols that seem to work — but "seem to work" is not a clinical trial.
What each compound contributes — and why it's in the stack.
Local tissue repair — angiogenesis, tendon/ligament healing, VEGFR2 activation
Full BPC-157 chapterSystemic healing — actin regulation, progenitor cell mobilization, anti-inflammation
Full TB-500 chapterBPC-157 and TB-500 hit different parts of the healing cascade. BPC-157 primarily drives local angiogenesis and growth factor upregulation at the injury site via VEGFR2; TB-500 (a Thymosin Beta-4 fragment) works more systemically — regulating actin polymerization, mobilizing stem cells, and suppressing pro-inflammatory cytokines. The mechanistic case for combining them is that local vascular repair (BPC) plus systemic anti-inflammatory and progenitor mobilization (TB-500) should be additive. No clinical trial has tested this directly.
This reflects how this combination is used in practice. It is not a prescribing guide and does not constitute medical advice.
| Phase | Timing | Compounds & doses | Notes |
|---|---|---|---|
| Loading (weeks 1–4) | Daily | BPC-157 500 mcg SC + TB-500 5–10 mg SC/IM 2×/week | Higher TB-500 dose in loading phase to establish baseline tissue levels |
| Maintenance (weeks 5–12) | Daily | BPC-157 250–500 mcg SC + TB-500 2–2.5 mg 1–2×/week | Drop TB-500 to maintenance frequency; BPC-157 continues daily near injury |
| Cycle off | 4+ weeks off | None | Both are research chemicals with no established long-cycle safety data. Cycling is the conservative default. |
Athletes or active individuals with acute tendon, ligament, or soft-tissue injury who have exhausted or are unwilling to wait for standard-of-care options. Most commonly run for rotator cuff, Achilles, patellar tendon, and ACL/MCL injuries. Also used post-surgically.
Informational only. Ranges vary significantly by vendor, vial size, and country. No pharmaceutical-grade source exists for most of these compounds; figures are not a buying guide.